13544-07-5

Usage

Uses

Methyl (2-nitro-4-trifluoromethylphenyl)acetate

InChI:InChI=1/C10H8F3NO4/c1-18-9(15)4-6-2-3-7(10(11,12)13)5-8(6)14(16)17/h2-3,5H,4H2,1H3

Upstream product

• 65754-26-9 2-methyl-5-trifluoromethylnitrobenzene 
• 290825-52-4 dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 
• 98-56-6 4-chlorobenzotrifluoride 
• 13544-04-2 Ethyl 2-cyano-2-(2-nitro-4-(trifluoromethyl)phenyl)acetate 
• 67-56-1 methanol 
• 1735-91-7 2-(2-nitro-4-(trifluoromethyl)phenyl)acetic acid 

Downstream Products

• 13544-08-6 <2-Amino-4-trifluormethyl-phenyl>-essigsaeure-methylester 
• 877766-69-3 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-propionic acid ethyl ester 
• 877768-45-1 trans-2-[1-(2,4-dichloro-benzyl)-6-trifluoromethyl-1H-indazol-3-yl]-cyclopropanecarboxylic acid 
• 877773-17-6 6-Trifluoromethyl-1H-indazole-3-carboxylic acid methyl ester 
• 877766-37-5 methyl 1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazole-3-carboxylate 
• 877773-19-8 2-(2,4-dichlorobenzyl)-6-trifluoromethyl-2H-indazole-3-carboxylic acid methyl ester 
• 877773-21-2 1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazole-3-carbaldehyde 
• 877768-41-7 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-oxirane-2-carboxylic acid 
• 877772-09-3 (1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazol-3-yl)methanol 
• 877766-45-5 (E)-3-(1-(2,4-dichlorobenzyl)-6-(trifluoromethyl)-1H-indazol-3-yl)acrylic acid 
• 877768-84-8 H₂-gamendazole 
• 877766-73-9 3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-acrylic acid ethyl ester 
• 877773-31-4 3-[1-(2,4-Dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-acrylic acid ethyl ester 
• 877768-95-1 3-[1-(2,4-dichlorobenzyl)-5-trifluoromethyl-1H-indazol-3-yl]-propionic acid 

Relevant academic research and scientific papers

PIII/PV=O Catalyzed Cascade Synthesis of N-Functionalized Azaheterocycles

An organocatalytic method for the modular synthesis of diverse N-aryl and N-alkyl azaheterocycles (indoles, oxindoles, benzimidazoles, and quinoxalinediones) is reported. The method employs a small-ring organophosphorus-based catalyst (1,2,2,3,4,4-hexamethylphosphetane P-oxide) and a hydrosilane reductant to drive the conversion of ortho-functionalized nitroarenes into azaheterocycles through sequential intermolecular reductive C?N cross coupling with boronic acids, followed by intramolecular cyclization. This method enables the rapid construction of azaheterocycles from readily available building blocks, including a regiospecific approach to N-substituted benzimidazoles and quinoxalinediones.

LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT

Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

Lonidamine analogues and their use in male contraception and cancer treatment

Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.

BISARYLUREA DERIVATIVES

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors

The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.

3-heteroarylidene-2-indolinone protein kinase inhibitors

The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors

The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.